IBA - Continued progress foreseen over '24
Post FY results and analyst meeting, we raised 24e and 25e revenue expectations by 3% and 2% respectively. REBIT is upped 16% in 24e and 3% in 25e. REBIT margin of 10% by 2026 is still envisaged, in line with guidance. We lowered working capital outflow as we were being too negative.Management reiterated during the analyst meeting that, although we will already see progress at PT level in '24, the real acceleration is only foreseen by '25 when they will start to deliver the Spanish contract. In the meantime, OA and dosimetry are foreseen to continue growing, albeit at aIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.